ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Bayer and Novo Nordisk side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

BayerNovo Nordisk
studies on the registry1,6941,454
open to participants now60114
phase 3 studies under way1155
reach primary completion within a year3563
programswith a study of their own in two years2143+14 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseBayerNovo Nordisk
Phase 119%

Novo Nordisk: 26 of its 43 programs at phase 1

  1. NNC0537-1482phase 1
  2. NNC0442-0344phase 1
  3. NNC0581-0001phase 1
  4. coramitugphase 1
  5. Gastric Inhibitory Polypeptidephase 1

and 21 more — sign in to see them all

60%
Phase 2

Bayer: 8 of its 21 programs at phase 2

  1. AB-1005phase 2
  2. WRN Inhibitor RO7589831phase 2
  3. nurandociguatphase 2
  4. BAY 3401016phase 2
  5. BAY 3670549phase 2

and 3 more — sign in to see them all

38%

Novo Nordisk: 6 of its 43 programs at phase 2

  1. NNC0662-0419phase 2
  2. UBT251phase 2
  3. CDR132Lphase 2
  4. NNC0519-0130phase 2
  5. zalferminphase 2

and 1 more — sign in to see them all

14%
Phase 3

Bayer: 4 of its 21 programs at phase 3

  1. elinzanetantphase 3
  2. sevabertinibphase 3
  3. bemdaneprocelphase 3
  4. aficamtenphase 3
19%

Novo Nordisk: 7 of its 43 programs at phase 3

  1. zenagamtidephase 3
  2. cagrilintidephase 3
  3. etavopivatphase 3
  4. ziltivekimabphase 3
  5. efruxiferminphase 3

and 2 more — sign in to see them all

16%
Approved, new studies

Bayer: 5 of its 21 programs at approved, new studies

  1. finerenoneapproved, new study
  2. darolutamideapproved, new study
  3. Aspirinapproved, new study
  4. acoramidisapproved, new study
  5. Levonorgestrelapproved, new study
24%

Novo Nordisk: 4 of its 43 programs at approved, new studies

  1. Semaglutideapproved, new study
  2. Liraglutideapproved, new study
  3. insulin icodecapproved, new study
  4. recombinant FVIIaapproved, new study
9%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Bayer10 readouts · 4 phase 3·

Bayer, Dec ’26: 1 program whose next study reaches primary completion

  1. BAY 3389934phase 1 · Dec 25 · NCT06854640

Bayer, Jan ’27: 1 program whose next study reaches primary completion

  1. elinzanetantphase 3 · Jan 22 · NCT07762287
·

Bayer, Mar ’27: 1 program whose next study reaches primary completion

  1. Aspirinapproved, new study · Mar 10 · NCT07652723

Bayer, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. finerenoneapproved, new study · Apr 10 · NCT05196035

Bayer, May ’27: 2 programs whose next study reaches primary completion

  1. nurandociguatphase 2 · May 7 · NCT07431294
  2. WRN Inhibitor RO7589831phase 2 · May 31 · NCT06004245
·

Bayer, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. darolutamideapproved, new study · Jul 30 · NCT05794906

Bayer, Aug ’27: 1 program whose next study reaches primary completion

  1. RAS/PI3K-alpha Inhibitor VVD-159642phase 1 · Aug 1 · NCT06804824

Bayer, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. acoramidisapproved, new study · Sep 17 · NCT07298044

Bayer, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. sevabertinibphase 3 · Oct 28 · NCT06452277
Novo Nordisk24 readouts · 4 phase 3·

Novo Nordisk, Dec ’26: 4 programs whose next study reaches primary completion

  1. Liraglutideapproved, new study · Dec 13 · NCT07225816
  2. Semaglutideapproved, new study · Dec 13 · NCT07225816
  3. NNC0662-0419phase 2 · Dec 14 · NCT07184632
  4. CDR132Lphase 2 · Dec 31 · NCT07656454

Novo Nordisk, Jan ’27: 8 programs whose next study reaches primary completion, 2 in phase 3

  1. UBT251phase 2 · Jan 14 · NCT07395687
  2. NNC0537-1482phase 1 · Jan 15 · NCT07218627
  3. NNC4004-0002phase 1 · Jan 19 · NCT06859073
  4. NNC6989-0001phase 1 · Jan 21 · NCT07437079
  5. insulin icodecapproved, new study · Jan 25 · NCT07076199

and 3 more — sign in to see them all

Novo Nordisk, Feb ’27: 1 program whose next study reaches primary completion

  1. NNC0442-0344phase 1 · Feb 5 · NCT07220564

Novo Nordisk, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. cagrilintidephase 3 · Mar 1 · NCT07011667
·

Novo Nordisk, May ’27: 2 programs whose next study reaches primary completion

  1. NNC4005-001phase 1 · May 14 · NCT07214870
  2. coramitugphase 1 · May 30 · NCT07448623
··

Novo Nordisk, Aug ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. NNC0705-0002phase 1 · Aug 1 · NCT07797855
  2. NNC6022-0004phase 1 · Aug 3 · NCT07693868
  3. etavopivatphase 3 · Aug 20 · NCT05953584
  4. recombinant FVIIaapproved, new study · Aug 26 · NCT07157423

Novo Nordisk, Sep ’27: 3 programs whose next study reaches primary completion

  1. NNC0642-1895phase 1 · Sep 12 · NCT07829406
  2. INV-347phase 1 · Sep 15 · NCT07153172
  3. NNC0721-8060phase 1 · Sep 23 · NCT07767175

Novo Nordisk, Oct ’27: 1 program whose next study reaches primary completion

  1. NNC0581-0001phase 1 · Oct 11 · NCT06891365
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Bayer

New programs 0

None

Reached a new phase 1

Study stopped 0

None

Primary completion later 2

Novo Nordisk

New programs 5

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Where they overlap

Conditions where at least two of them have programs: 8 in all. A program counts in each condition its studies name most.

ConditionBayerNovo Nordisk
Diabetes Mellitus, Type 2both · compare here

Bayer in Diabetes Mellitus, Type 2: 2 programs

  1. finerenoneapproved, new study
  2. Levonorgestrelapproved, new study

Their studies: Bayer’s studies of Diabetes Mellitus, Type 2 in search

Novo Nordisk in Diabetes Mellitus, Type 2: 13 programs

  1. zenagamtidephase 3
  2. cagrilintidephase 3
  3. efruxiferminphase 3
  4. NNC0662-0419phase 2
  5. UBT251phase 2

and 8 more — sign in to see them all

Their studies: Novo Nordisk’s studies of Diabetes Mellitus, Type 2 in search

Renal Insufficiency, Chronicboth · compare here

Bayer in Renal Insufficiency, Chronic: 2 programs

  1. nurandociguatphase 2
  2. finerenoneapproved, new study

Their studies: Bayer’s studies of Renal Insufficiency, Chronic in search

Novo Nordisk in Renal Insufficiency, Chronic: 5 programs

  1. cagrilintidephase 3
  2. ziltivekimabphase 3
  3. NNC0519-0130phase 2
  4. NNC0537-1482phase 1
  5. NNC0705-0001phase 1

Their studies: Novo Nordisk’s studies of Renal Insufficiency, Chronic in search

Heart Failureboth · compare here

Bayer in Heart Failure: 1 program

  1. finerenoneapproved, new study

Their studies: Bayer’s studies of Heart Failure in search

Novo Nordisk in Heart Failure: 3 programs

  1. ziltivekimabphase 3
  2. CDR132Lphase 2
  3. NNC0537-1482phase 1

Their studies: Novo Nordisk’s studies of Heart Failure in search

Carcinoma, Non-Small-Cell Lungboth · compare here

Bayer in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. sevabertinibphase 3
  2. PRMT5 Inhibitor BAY 3713372phase 2

Their studies: Bayer’s studies of Carcinoma, Non-Small-Cell Lung in search

Novo Nordisk in Carcinoma, Non-Small-Cell Lung: 1 program

  1. Digoxinphase 1

Their studies: Novo Nordisk’s studies of Carcinoma, Non-Small-Cell Lung in search

Coronary Artery Diseaseboth · compare here

Bayer in Coronary Artery Disease: 2 programs

  1. nurandociguatphase 2
  2. Aspirinapproved, new study

Their studies: Bayer’s studies of Coronary Artery Disease in search

Novo Nordisk in Coronary Artery Disease: 1 program

  1. ziltivekimabphase 3

Their studies: Novo Nordisk’s studies of Coronary Artery Disease in search

Amyloidosisboth · compare here

Bayer in Amyloidosis: 1 program

  1. acoramidisapproved, new study

Their studies: Bayer’s studies of Amyloidosis in search

Novo Nordisk in Amyloidosis: 1 program

  1. coramitugphase 1

Their studies: Novo Nordisk’s studies of Amyloidosis in search

Cardiovascular Diseasesboth · compare here

Bayer in Cardiovascular Diseases: 1 program

  1. Aspirinapproved, new study

Their studies: Bayer’s studies of Cardiovascular Diseases in search

Novo Nordisk in Cardiovascular Diseases: 1 program

  1. cagrilintidephase 3

Their studies: Novo Nordisk’s studies of Cardiovascular Diseases in search

Neoplasmsboth · compare here

Bayer in Neoplasms: 1 program

  1. darolutamideapproved, new study

Their studies: Bayer’s studies of Neoplasms in search

Novo Nordisk in Neoplasms: 1 program

  1. Digoxinphase 1

Their studies: Novo Nordisk’s studies of Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetBayerNovo Nordisk
TTRacoramidisrulecoramitug, coramitug
A target, or a pathogen for a vaccine, known for: Bayer 13 of 21 · Novo Nordisk 17 of 43 programs (19 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Novo Nordisk: 14).